Who are Botulinum Toxin Type A - Vistabel's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): DWC202404, DWC202314P, DWC202313, DWC202314, DWC202405, DWC202314P, DWC202313, DWC202314P, Rocuronium, Tracrium Preservative Free.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/botulinum-toxin-type-a-vistabel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Botulinum Toxin Type A - Vistabel — Competitive Intelligence Brief

Botulinum Toxin Type A - Vistabel (Botulinum Toxin Type A - Vistabel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neuromuscular blocking agent. Area: Neurology.

phase 2 Neuromuscular blocking agent Botulinum toxin type A Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Botulinum Toxin Type A - Vistabel (Botulinum Toxin Type A - Vistabel) — Galderma R&D. Inhibits acetylcholine release at the neuromuscular junction

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Botulinum Toxin Type A - Vistabel TARGET	Botulinum Toxin Type A - Vistabel	Galderma R&D	phase 2	Neuromuscular blocking agent	Botulinum toxin type A
DWC202404, DWC202314P	DWC202404, DWC202314P	Daewoong Pharmaceutical Co. LTD.	phase 3	botulinum toxin type A inhibitor	botulinum toxin type A
DWC202313, DWC202314	DWC202313, DWC202314	Daewoong Pharmaceutical Co. LTD.	phase 3	botulinum toxin type A inhibitor	botulinum toxin type A
DWC202405, DWC202314P	DWC202405, DWC202314P	Daewoong Pharmaceutical Co. LTD.	phase 3	botulinum toxin type A inhibitor	botulinum toxin type A
DWC202313, DWC202314P	DWC202313, DWC202314P	Daewoong Pharmaceutical Co. LTD.	phase 3	botulinum toxin type A inhibitor	botulinum toxin type A
Rocuronium	Rocuronium Bromide	Merck & Co.	marketed	Nondepolarizing neuromuscular blocking agent	Cholinergic receptors at the motor end-plate	1994-01-01
Tracrium Preservative Free	Atracurium Besylate	Pfizer Inc.	marketed	Nondepolarizing neuromuscular blocking agent	Cholinergic receptor sites on motor end-plate	1983-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2039-07-22 — Rocuronium · 11998605 · Formulation · US

Sponsor landscape (Neuromuscular blocking agent class)

Galderma R&D · 2 drugs in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Fondation Ophtalmologique Adolphe de Rothschild · 1 drug in this class
Allergan · 1 drug in this class
Seganest · 1 drug in this class
University of California, Los Angeles · 1 drug in this class
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Botulinum Toxin Type A - Vistabel — Competitive Intelligence Brief. https://druglandscape.com/ci/botulinum-toxin-type-a-vistabel. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab